Randomised phase II trial of mFOLFOX6 plus bevacizumab versus mFOLFOX6 plus cetuximab as first-line treatment for colorectal liver metastasis (ATOM trial)

BACKGROUND: Chemotherapy with biologics followed by liver surgery improves the resection rate and survival of patients with colorectal liver metastasis (CRLM). However, no prospective study has compared the outcomes of chemotherapy with bevacizumab (BEV) versus cetuximab (CET). METHODS: The ATOM stu...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Br J Cancer
Prif Awduron: Oki, Eiji, Emi, Yasunori, Yamanaka, Takeharu, Uetake, Hiroyuki, Muro, Kei, Takahashi, Takao, Nagasaka, Takeshi, Hatano, Etsuro, Ojima, Hitoshi, Manaka, Dai, Kusumoto, Tetsuya, Katayose, Yu, Fujiwara, Toshiyoshi, Yoshida, Kazuhiro, Unno, Michiaki, Hyodo, Ichinosuke, Tomita, Naohiro, Sugihara, Kenichi, Maehara, Yoshihiko
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Nature Publishing Group UK 2019
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6738101/
https://ncbi.nlm.nih.gov/pubmed/31285591
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-019-0518-2
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg